Navigation Links
Auxilium Pharmaceuticals to Present at the Leerink Swann 2012 Global Healthcare Conference
Date:2/1/2012

MALVERN, Pa., Feb. 1, 2012 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL) today announced that executive management will participate in the Leerink Swann 2012 Global Healthcare Conference to be held February 15-16, 2012 at the Waldorf Astoria in New York City.  Mr. Adrian Adams, Chief Executive Officer and President, is scheduled to present an overview of the Company and its product pipeline at 10:30 a.m. ET on Wednesday, February 15, 2012.

(Logo:  http://photos.prnewswire.com/prnh/20101202/MM10881LOGO )

The presentation slides to be used during the call will be available on the "For Investors" section of the Auxilium web site under the "Presentations" tab on February 15, 2012.  The presentation and the presentation slides will be simultaneously web cast on the "For Investors" section of the Auxilium web site under the "Events" tab on February 15, 2012.  A question and answer session will follow the presentation and will be webcast.  To access the live webcast, please log on to Auxilium's site approximately fifteen minutes prior to the presentation to register and download any necessary audio software.  The presentation replay will be available for ninety days after the event.About AuxiliumAuxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company with a focus on developing and marketing products to predominantly specialist audiences, such as urologists, endocrinologists, certain targeted primary care physicians, hand surgeons, subsets of orthopedic, general, and plastic surgeons who focus on the hand, and rheumatologists. Auxilium markets XIAFLEX® (collagenase clostridium histolyticum) for the treatment of adult Dupuytren's contracture patients with a palpable cord and Testim® 1%, a testosterone gel, for the topical treatment of hypogonadism in the U.S. Pfizer has marketing rights for XIAPEX® (the EU tradename for collagenase clostridium histolyticum) in Europe and Asahi Kasei Pharma Corporation has development and commercial rights for XIAFLEX in Japan. Ferring International Center S.A. markets Testim in the EU and Paladin Labs Inc. markets Testim in Canada. Auxilium has three projects in clinical development. XIAFLEX is in phase III of development for the treatment of Peyronie's disease, in phase IIa of development for the treatment of Frozen Shoulder syndrome (Adhesive Capsulitis) and in phase Ib of development for the treatment of cellulite (edematous fibrosclerotic panniculopathy). Auxilium also has rights to pursue additional indications for XIAFLEX. For additional information, visit http://www.auxilium.com.

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995This release contains "forward-looking-statements" within the meaning of The Private Securities Litigation Reform Act of 1995, including statements regarding the Company's intention to present at the Leerink Swann 2012 Global Healthcare Conference; and products in development for Peyronie's disease, Frozen Shoulder syndrome and cellulite; and all other statements containing projections, statements of future performance or expectations, our beliefs or statements of plans or objectives for future operations (including statements of assumption underlying or relating to any of the foregoing). Forward-looking statements can generally be identified by words such as "believe," "appears," "may," "could," "will," "estimate," "continue," "anticipate," "intend," "should," "plan," "expect," and other words and terms of similar meaning in connection with any discussion of projections, future performance or expectations, beliefs, plans or objectives for future operations (including statements of assumption underlying or relating to any of the foregoing). Actual results may differ materially from those reflected in these forward-looking statements due to various factors, including further evaluation of clinical data, results of clinical trials, decisions by regulatory authorities as to whether and when to approve drug applications, and general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries and those discussed in Auxilium's Annual Report under the heading "Risk Factors" on Form 10-K for the year ended December 31, 2010 and in Auxilium's Quarterly Report on Form 10-Q for the quarter ended September 30, 2011, which are on file with the Securities and Exchange Commission (the "SEC") and may be accessed electronically by means of the SEC's home page on the Internet at http://www.sec.gov or by means of Auxilium's home page on the Internet at http://www.Auxilium.com under the heading "For Investors -- SEC Filings." There may be additional risks that Auxilium does not presently know or that Auxilium currently believes are immaterial which could also cause actual results to differ from those contained in the forward-looking statements. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements.

In addition, forward-looking statements provide Auxilium's expectations, plans or forecasts of future events and views as of the date of this release. Auxilium anticipates that subsequent events and developments will cause Auxilium's assessments to change. However, while Auxilium may elect to update these forward-looking statements at some point in the future, Auxilium specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Auxilium's assessments as of any date subsequent to the date of this release.

 For More Information, Contact:

 

 James E. Fickenscher / CFOWilliam Q. Sargent, Jr. / V.P., IR  Auxilium Pharmaceuticals, Inc.Auxilium Pharmaceuticals, Inc.(484) 321-59(484) 321-5900jfickenscher@auxilium.comwsargent@auxilium.com


'/>"/>

SOURCE Auxilium Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Announces First Patients Dosed in XIAFLEX® Phase Ib Cellulite Study
2. Auxilium Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
3. Auxilium Pharmaceuticals, Inc. Announces First Patient Dosed in XIAFLEX® Study for Frozen Shoulder Syndrome
4. Auxilium Pharmaceuticals to Present at the Oppenheimer 22nd Annual Healthcare Conference
5. Auxilium Pharmaceuticals, Inc. Announces Publication of U.S. CPT® Codes and Related Reimbursement Rates for XIAFLEX®
6. Auxilium Pharmaceuticals to Announce Third Quarter 2011 Results and Conduct Conference Call on Monday, October 31, 2011
7. Auxilium Pharmaceuticals Announces Additional Data from Three-Year XIAFLEX® Recurrence Study in Dupuytrens Contracture in E-poster at ASSH Meeting
8. Auxilium Pharmaceuticals Announces Positive Data from Commercial Patient Chart Review in E-posters at ASSH Meeting
9. Auxilium Pharmaceuticals, Inc. Announces Positive Top-Line Results from XIAFLEX® Multi-Cord Study
10. Auxilium Pharmaceuticals, Inc. and BioSpecifics Technologies Corp. Announce Plans to Develop Additional Indications using XIAFLEX®
11. Auxilium Pharmaceuticals Announces Investor Event to Occur at 2011 ASSH Meeting on September 9, 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/5/2020)... ... August 04, 2020 , ... ... 2016 and has continued to refine their medical device assessment and penetration ... medical device manufacturing facilities to provide testing onsite, at client facilities. Due ...
(Date:8/5/2020)... ... August 04, 2020 , ... Millions of America’s ... their health and quality of life unless Congress and the Centers for Medicare ... (ASHA) warns today. , At issue is CMS’s 2021 proposed Medicare ...
(Date:8/3/2020)... S.C. (PRWEB) , ... August 03, 2020 , ... Hide-a-Mask, ... Kickstarter raising over $36,000 in less than three weeks since launch. Hide-a-Mask is ... “We are grateful for our early backers who, like us, believe having a mask ...
Breaking Medicine Technology:
(Date:8/11/2020)... (PRWEB) , ... August 11, 2020 , ... Help.org ... ones, has announced the Best Rehab Facilities in Greenville, for 2020. The informational ... services and more. , According to recent studies , drug overdose is ...
(Date:8/11/2020)... ... August 11, 2020 , ... 2020 has seen a drastic change in how things are ... recommended that everyone wears a face mask in public. Now, most states have made it ... , Earlier this year, all medical professionals in the U.S.A realized the shortage of PPE ...
(Date:8/9/2020)... , ... August 10, 2020 , ... Dr. Angela Abraham ... College of Optometry (NECO). Dr. Abraham will be leading the drive to foster a ... signed on to the 13% Promise, a new initiative led by Black Eyecare Perspective ...
(Date:8/7/2020)... (PRWEB) , ... August 07, 2020 , ... ... Duke Street in Alexandria, Virginia. Led by Dr. Mojgan Mazhari, this well-respected practice ... Alexandria Dental Health & Smile Studio is among an exclusive group of dental ...
(Date:8/5/2020)... LOS ANGELES (PRWEB) , ... August 05, 2020 ... ... most used Social Emotional Learning (SEL) program, has been named to the inaugural ... of School Librarians (AASL). , This recognition honors electronic resources that provide ...
Breaking Medicine News(10 mins):